CPI at TIDES USA: Oligonucleotide and Peptide Therapeutics
Tue, 14 May 2024
Speaker
Barrie Cassey
Medicines Manufacturing Technology Lead, CPI
A successful pharmaceutical and biotechnology technical leader with significant experience in a wide range of areas including process development, GMP manufacturing, technology transfer, and bringing innovation into commercial use. As a technically astute natural leader, Barrie has created and led teams from 1 to 100 whilst delivering complex and commercially critical projects.
Next steps
Oligonucleotides are a revolutionary new therapeutic in the pharma industry. These short, chemically synthesised fragments of DNA or RNA modulate protein expression through several different mechanisms to treat the underlying drivers of disease.
They can cover a wide variety of diseases, from cancer to Alzheimer’s, and have the potential to unlock medicines for conditions currently considered untreatable and create more effective medicines for larger patient populations such as heart disease.
Eager to find out more? I’d love to have a conversation about how we can work together.
To receive a copy of an introductory slide deck on the current Oligonucleotide projects currently underway at CPI, simply fill out the short form below.